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Cerebral malaria (CM) is the deadliest form of severe Plasmodium infections. Currently, we have 
limited understanding of the mechanisms by which Plasmodium parasites induce CM. The mouse 
model of CM, experimental CM (ECM), induced by infection with the rodent parasite, Plasmodium 
berghei AnKA (PbANKA) has been extensively used to study the pathophysiology of CM. Recent 
genomic analyses revealed that the coding regions of PbAnKA and the closely related Plasmodium 
berghei NK65 (PbNK65), that does not cause ECM, differ in only 21 single nucleotide polymorphysims 
(SNPs). Thus, the SNP-containing genes might contribute to the pathogenesis of ECM. Although 
the majority of these SNPs are located in genes of unknown function, one SNP is located in the DNA 
binding site of a member of the Plasmodium ApiAP2 transcription factor family, that we recently 
showed functions as a virulence factor alternating the host’s immune response to the parasite. Here, 
we investigated the impact of this SNP on the development of ECM. Our results using CRISPR-Cas9 
engineered parasites indicate that despite its immune modulatory function, the SNP is neither 
necessary nor sufficient to induce ECM and thus cannot account for parasite strain-specific differences 
in ECM phenotypes.
Malaria is a global health problem accounting for over 200 million cases each year worldwide and nearly 450,000 
deaths in Africa alone, the majority of which are young  children1,2. Malaria is caused by mosquito-borne parasites 
belonging to genus Plasmodium that have complex life cycles involving two  hosts3. The outcome of the Plasmo-
dium infection can vary from asymptomatic infections, to mild febrile disease, to severe malaria, the most deadly 
form of which is cerebral malaria (CM)3–7. Approximately 1–2% of children with malaria develop CM that is 
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accompanied by sequestration of infected RBCs (iRBCs) in the brain vasculature, blood brain barrier dysfunc-
tion, brain swelling and ultimately herniation of the brain stem and  death6–8. CM mortality is high, 15–25%, and 
tragically, approximately 25% of children who recover from CM suffer from long-term neurological sequalae, 
including cognitive, vision and hearing  impairments7.
An important tool for the study of CM is the mouse model of CM, namely experimental CM (ECM). ECM is 
induced by infection of susceptible mouse strains such as C57BL/6 with the ECM-causing rodent Plasmodium 
strain, PbANKA that recapitulates many of the features of CM in children both clinically and  pathologically7–14. 
PbANKA infection results in the rapid progression of disease, leading to development of as ataxia, paralysis and 
coma accompanied by brain hemorrhages, iRBC sequestration in brain vessels, edema, and if left untreated, 
within 5–7 days post infection, death, likely by neuronal cell death in the brain  stem11,12. Repeated high resolu-
tion brain MRI monitoring of PbANKA-infected mice showed radiological findings indicating vasogenic edema 
and blood brain barrier (BBB) disruption similar to cerebral pathology described by MRI in children with  CM13. 
Mice treated with anti-malarials when neurological symptoms first appear, as is the standard of care for children, 
show long-term cognitive  dysfunction13. In the mouse model  CD8+ T cells that migrate to and sequester in the 
brain vasculature have been demonstrated to be directly responsible for ECM  mortality15. Because only a few 
histopathological studies reported leukocyte accumulation in the brains of children who died of CM, the ECM 
model was deemed  questionable16. However, a recent demonstration of  CD8+ T cells in contact with the brain 
endothelium in children who died of CM but not of other causes, provided strong evidence that the mouse model 
accurately reflects the human disease  pathology17. Therefore, ECM is an important animal model that has the 
potential to increase field’s understanding of this deadly disease.
In contrast, a highly related strain to PbANKA, PbNK65, causes severe anemia in the absence of any detectable 
brain  pathology18,19. A comparison of high coverage genomic sequences of PbANKA and PbNK65 revealed that 
these two strains differ by only 21 single nucleotide polymorphisms (SNPs) in their coding regions (Table 1)20. 
Thus, remarkably, a small number of SNPs may account for the dramatically different disease outcomes of 
infection with PbANKA versus PbNK65. The majority of the genes containing SNPs are of unknown function, 
however, two SNPs were identified in genes encoding proteins belonging to ApiAP2 transcriptional factor (TF) 
family namely PBANKA_0112100 and PBANKA_1415700. The SNP in PBANKA_1415700 was located imme-
diately before the stop codon and hence unlikely to induce structural alterations that would lead to functional 
differences in the expressed ApiAP2 (Table 1). On the other hand, the SNP in PBANKA_0112100 was located 
in the predicted DNA-binding domain of ApiAP2 resulting in a substitution of a Serine (S) to Phenylalanine (F) 
at amino acid 1823 in the expressed protein, two biochemically distinct amino acids. Therefore, this SNP had 
the potential to influence the function of ApiAP2.
PBANKA_0112100 is an essential transcription factor and therefore no viable knock out could be  generated21. 
Until recently it was a gene of unknown function which is expressed in the schizonts during the blood stage 
of Plasmodium life  cycle21. However, our thorough genetic and functional analysis using this SNP in order 
to dissect out the function of this transcription factor revealed that the SNP in the DNA binding region of 
PBANKA_0112100 alters the expression of 46 Plasmodium genes. Among these 46 genes 39 belong to either 
BIR(22/46), fam-a (7/46), fam-b ( 8/46) or fam-c (2/46) gene families all of which are known to be involved in 
virulence and evasion related  functions22. Based on these changes we have observed differences in host pathogen 
interaction including changes in protective immune responses against the  parasite22. Despite these published 
findings whether or not this SNP alters the progression of ECM is not clear. Here we address a possible link 
between this polymorphism in ApiAP2 and the development of ECM.
Results
CRISPR-Cas9 gene editing strategy generated two viable mutant parasites. In order to test 
whether the SNP leading to non-synonymous S to F substitution in  1823rd amino acid of the ApiAP2 TF family 
member PBANKA_0112100 plays a role in the development of ECM, we engineered two distinct transgenic 
parasites; PbNK65F that contained an S → F substitution and PbANKAS that contained F → S substitution at 
position 1823 in the PbNK65 and PbANKA WT parasite backgrounds, respectively using CRISPR-Cas9 (Sup-
plementary Fig. 1). A single plasmid (pYC) system as described by Zhang et al. for gene editing in P. yoelii was 
used to introduce the SNP at 1823 position in  ApiAP223. The pYC plasmid contains all the essential compo-
nents of CRISPR-Cas9 that are required for successful genome editing. Our earlier and present work demon-
strate successful use of pYC for genome editing of P. berghei in addition to its initial usage for P. yoelii genome 
 engineering23. A guide region of 20 nucleotides was manually selected near amino acid position 1823 that fol-
lowed the PAM motif (Supplementary Fig. 1A). The guide was cloned upstream of tracrRNA sequence in pYC to 
enable PyU6 promoter driven expression of gRNA:tracrRNA  chimera23. The desired mutation was incorporated 
in the transgenic parasites along with shield mutations that were introduced in the modified locus to avoid 
recognition by the Cas9 endonuclease (Supplementary Fig. 1A). The desired and the shield mutations were part 
of synthetic gene sequence that was also encoded in pYC plasmid (see Supplementary Information). The incor-
poration of the desired substitution (F → S) in AP2 gene of  PbANKAS was confirmed by DNA sequencing (Sup-
plementary Fig. 1B). We compared infections by the mutant parasites PbNK65F and PbANKAS in C57BL/6 mice 
to infections with their WT counterparts PbNK65S and PbANKAF, respectively. Notably, we have recently func-
tionally characterized the transgenic  PbNK65F parasites and found that the mutant AP2 is involved in mounting 
protective immune response in the infected host that is positively correlated with host survival in second chal-
lenge with either the WT or the mutant strain of  PbNK6522.
PbNK65f does not induce ECM. We first compared infections of C57BL/6 mice with the mutant PbNK65F 
parasite to infections with ECM-inducing WT PbA and non-ECM-inducing WT PbNK65S. Mice were inocu-
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lated with  106 iRBCs. As expected, WT PbANKAF infections resulted in relatively low parasitemia levels over 
seven days, with rapid reductions in hemoglobin levels to 8 g/dl, worsening clinical symptoms and 100% mortal-
ity by day 7 post infection (d7p.i.) (Fig. 1). In contrast, infection with WT-PbNK65S showed increases in para-
sitemia reaching 40% by d20p.i., with a decrease in hemoglobin levels to 2 g/dl, worsening clinical symptoms 
beginning around d15p.i. and 100% mortality by d25p.i. This disease progression was nearly identical for mice 
infected with the mutant PbNK65F indicating that the  AP2F mutation in PbNK65 did not alter the course of the 
non-CM infection of WT-PbNK65S to resemble infections by the CM-causing WT-PbANKAF.
ECM is accompanied by loss in BBB function by d6 p.i. as measured by leakage of Evans blue dye into 
the  brain11,12. To determine if PbNK65F induced cerebral pathology, we examined the brains of mice eutha-
nized shortly after Evans blue was administered intravenously either at d6 p.i. for WT PbANKAF or d21 p.i. for 
WT PbNK65S and PbNK65F (Fig. 2A). As expected, brains from PbANKAF -infected animals showed loss of 
BBB integrity predominantly in the olfactory bulbs of the brain. In contrast, the brains of WT PbNK65S- and 
Table 1.  Locations of all 21 SNPs that are different between the coding regions of ECM causing PbANKA and 
non-ECM causing PbNK65 parasites.
SNP Gene ID Product Length
Position of 
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Figure 1.  S1823F mutation in ApiAP2 TF of PbNK65 does not alter the progression of infection. (A–D) 
C57BL/6 mice were inoculated intraperitoneally with WT PbANKAF-, WT PbNK65S- and mutant PbNK65 F 
iRBCs  (106/mouse). Peripheral parasitemia given as percent of RBC that are infected (A), hemoglobin levels 
(g/dl) (B), clinical symptoms measured by evaluating motor abilities based on a 10 point scale (higher scores 
correspond more advanced disease) outlined in methods (C), and survival (D) are shown for each group with 
time (days) post infection. Each circle in (A–C) represents an individual mouse and lines represent mean values. 
Data is representative of three independent experiments each carried out with at least 10 mice per group.
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PbNK65F-infected mice appeared similar to brains of uninfected control animals albeit paler, likely related to 
their severe anemic states. Histopathological evaluation of brain sections showed that signs indicative of ECM 
including hemorrhage in the cerebellum and olfactory bulb, and iRBC sequestration in the brain vasculature, 
were only observed in WT PbANKAF-infected mice but not in PbNK65F or WT PbNK65S-infected mice (Fig. 2B).
ECM is also accompanied by accumulation of  CD8+ T cells in the  brain6,11,12. We quantified the  CD8+ T cell 
accumulation in single cell preparation of the brains of WT PbNK65S- and mutant PbNK65F-infected mice using 
a double leukocyte staining strategy detailed in the methods section. We observed no difference in the quanti-
ties of  CD8+ T cells between PbNK65S- and PbNK65F-infected mice (Fig. 3A,B) at either d10 p.i. or d21 p.i. We 
quantified iRBC sequestration in brains, another sign of ECM  patology11,12 using qPCR and observed no differ-
ences between PbNK65F- and PbNK65S-infected mice (Fig. 3C). Taken together these results demonstrate that 
the introduction of an S → F substitution in PbNK65 is not sufficient to convert a non-ECM inducing parasite 
into an ECM generating parasite.
PbANKAS induces ECM. Thus far our investigations revealed that S1823F mutation in the DNA binding 
domain of ApiAP2 TF PBANKA_0112100 of non-ECM generating rodent Plasmodium strain PbNK65 was not 
sufficient to induce ECM in infected mice. However, it is possible that  AP2F, although not sufficient to induce 
ECM when expressed on genetic background of a non-ECM inducing parasite, might be necessary for ECM 
induction in WT-PbANKA-infected mice. We evaluated symptoms of ECM in mice infected with  106 WT-
PbANKAF iRBCs with the mutant PbANKAS iRBCs. Evans blue staining showed comparable BBB dysfunction 
at d6 p.i. (Fig. 4A) and histopathological evaluation of brain sections confirmed cerebral hemorrhages and intra-
vasculature sequestrations of iRBCs (Fig. 4B). Thus, F at position 1823 in ApiAP2 does not appear necessary to 
induce ECM. We also determined the outcome of infections at a lower inoculation dose of iRBCs  (102 versus 
 106 iRBCs/mouse). We observed a delayed onset of the rise in parasitemia in mice receiving lower inoculum 
(Fig. 4C), however, the parasitemia reach comparable levels (~ 8%) (on d5p.i.) for mice given the high dose of 
iRBCs and (on d11p.i.) for mice given the low dose of iRBCs (Fig. 4C). Moreover, nearly 100% of mice died on 
d7 p.i. for mice given the high dose iRBCs or on d15 p.i. for mice given the low dose of iRBCs (Fig. 4D).
Discussion
CM is a deadly disease that not only claims the lives of African children each year but also leaves approximately 
25% of survivors with severe, debilitating neurological sequelae. At present there are no adjunctive therapies that 
given with anti-malaria drugs reduce CM mortality, that remains high at 15–25%. Clearly, a better understanding 
of the parasite genes that are necessary and/or sufficient for CM would benefit a search for new therapies. Here 
we investigated the contribution of a SNP that encodes amino acid 1823 in the TF ApiAP2 and differs between 
PbA parasites that cause CM and the closely related PbNK65 parasites that do not cause CM. This SNP was of 
particular interest as it is one of only 21 SNPs that differ between PbANKA and PbNK65.
Parasites deficient for PBANKA_0112100 cannot be generated due to the vital role of ApiAP2 in the blood 
stage  infection21. However, we recently showed that the SNP leading to S to F nonsynonymous amino acid 
substation at position 1823 of PBANKA_0112100 resulted in alteration of DNA binding site which resulted in 
the differential expression of 46 Pb genes, most of which were predicted to play a role in host pathogen interac-
tion and immune evasion strategies of the parasite. We showed that as compared to infections of mice with WT 
PbNK65 that resulted in the death of 100% of mice, infection with PbNK65F resulted in an early IFN-γ response 
and expansion of germinal centers leading to high levels of protective iRBC-specific TH1-type IgG2b and IgG2c 
antibodies. Thus, Pb ApiAP2 functioned as a critical parasite virulence factor in Pb  infections22. Whether or not 
this SNP altered the progression of ECM in infected mice was not studied.
Here we report that the SNP encoding F at position 1823 of the ApiAP2 TF is neither necessary for induction 
of ECM by PbANKA parasites nor sufficient for the induction of ECM by PbNK65 parasites. Detailed survival, 
parasitemia, clinical scoring, brain histopathology and sequestration analyses showed that the introduction of the 
F → S mutation in PbA-AP2 did not alter its ability to induce CM. Similar analyses showed that introduction of 
an S → F mutation in PbNK65 failed to generate a parasite capable of inducing ECM. Using a lower inoculum of 
the mutant and WT PbANKA, we showed that a 10,000-fold decrease in inoculum, although delaying the onset 
of the ECM symptoms, did not affect the disease outcome.
Based on these observations we conclude that the polymorphism in PBANKA_0112100 is neither sufficient 
nor necessary for induction of ECM. CM may result from complex interactions between different parasite genes. 
If this is the case mutations of multiple genes might be required to identify genetic contributions to the ECM 
phenotype, a costly and time-consuming process. However, further studies may reveal the functions of the cur-
rently uncharacterized 20 genes that differ between P. berghei NK65 and P. berghei ANKA and together, along 
with a thorough transcriptome analysis of these two parasites, may lead to identification of genetic variations 
that are collectively playing a role in the induction of ECM. Finally, noncoding elements of parasite genome may 
be exerting regulatory functions that collectively lead to a gene expression profile that would collectively lead to 
CM pheonotype. This possibility may only be addressed by in depth studies that are aimed towards identifying 
the differences between P. berghei NK65 and P. berghei ANKA in the noncoding parts of their genome and also 
having functional characterizations of noncoding regulatory elements.
Methods
Animals and Plasmodium strains. For all experiments, WT 8  weeks old C57BL/6 female mice, pur-
chased from Jackson Laboratories were used. Mice were maintained in NIAID animal facilities according to 
Animal Care and Use Committee guidelines. Experiments involving mice were approved by IACUC. WT Plas-
modium berghei NK65 (NYU) (PbNK65S) and WT Plasmodium berghei ANKA (PbANKAF) strains were used 
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for infections. PbNK65F mutant parasite was from stocks generated earlier for a previous project which had been 
confirmed as free of off-site  mutations22. Mutant PbA-AP2S was generated by employing a similar mutation and 
cloning strategies as has been described  earlier22.
Construction of plasmid for editing AP2 (PBANKA_0112100) in P. berghei ANKA. For editing 
the AP2 (PBANKA_0112100) gene in Plasmodium berghei ANKA, replacing phenylalanine 1823 with serine 
(F1823S), we used the clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated 
protein 9 (Cas9) system (CRISPR/Cas9)23. A single plasmid system containing pYC plasmid express all the 
essential components of CRISPR-Cas9; Cas9 endonuclease expressed as a fusion protein with drug selection 
marker hDHFR, gRNA:tracrRNA chimera driven by PyU6 promoter and a homology template for repair of 
double stranded break and concomitant introduction of desired mutation. A guide sequence of 20 nucleotides 
(5′ GCT GAA TTA AAA CCC CAA AG 3′), with protospacer adjacent motif (5′ AGG 3′), was selected by manual 
curation for targeting the Cas9 endonuclease to result in the desired editing (5,467 TTT to TCT) in the AP2 
gene. The 900 nucleotides of synthetic sequence (given in Supplementary Information) containing the mutated 
guide region and the desired single nucleotide polymorphism (SNP) (5,467 TTT to TCT) and shield mutations 
to overcome repeated restriction of the modified genomic locus, was sub-cloned in the pYC plasmid using NcoI 
and XhoI restriction enzyme sites. The resulting plasmid, pYC_ANKAAP2NK65, was used for the transfec-
tion of the P. berghei ANKA parasites. The P. berghei ANKA parasites were transfected with the plasmid pYC_
ANKAAP2NK65 as described earlier Successful editing of AP2 gene (PBANKA_0112100) in P. berghei ANKA 
was confirmed by DNA sequencing using the PCR strategy as described  earlier22,24,25. Briefly, oligos (AP2F: 5′ 
GAT TAT AGA TAC AAA TAA TGA GAA AAT GGG 3′ and AP2R: 5′ GCA TAT GTG ATA GTG TTA TTT CCA TC 3′) 
corresponding to ApiAP2 that were outside the boundary of the 900 bp homology template were used to PCR 
amplify the region of interest from transgenic  PbANKAS genomic sequence. The amplicon was DNA sequenced 
to verify the CRISPR mediated gene editing.
Infection of mice with infected red blood cells. Frozen stocks of parasite infected red blood cells 
were thawed and injected to donor C57BL/6 mice. Parasite levels in donor mice blood was checked routinely 
using flow cytometry-based strategies complemented with blood smear analysis as described  previously12. Once 
parasitemia reached around 5–10% donor blood was taken and then diluted to final concentration:  106 infected 
RBCs/mice for standard-dose inoculation and  102 infected RBCs/mice for low-dose inoculation using sterile 
PBS. Mice were infected with the desired inoculation dose through a single intraperitoneal injection of 200 µl 
infected RBC solution.
Analysis of disease progression. In order to analyze disease progression in experimental groups of para-
site infected animals, blood samples were taken routinely and parasitemia was measured using flow cytometry 
and/or smear, hemoglobin levels were measured using HemoCue Hb201 analyzer (HemoCue, Brea, CA, USA). 
Disease related worsening in motor abilities and general condition were assayed using 10-point clinical scor-
ing system that consists of 1-gait/posture/appearance, 2-cage grasp, 3-interactions/reflex, 4-visual placing, and 
5-capacity to hold their body weight on a baton. Each subcategory was scored 0 (healthy/normal), 1(moderate 
incapacitation) or 2 (total loss of ability)11,12. Mice were evaluated and scored by trained personnel in a single 
blind fashion routinely. A combined clinical score of 6 or above and hemoglobin levels of 2.5 g/dl or below 
were considered as end-point criteria and once animals reach either one of these criteria they were euthanized. 
Changes in the levels of parasite infected red blood cells (parasitemia) were monitored by routine blood analyses 
using a flow cytometry-based analysis developed  earlier12,26. These findings were later confirmed using blood 
smears prepared from the same samples.
Assessment of brain pathology. The integrity of blood brain barrier was evaluated by injecting the 
mice with 20  mg/kg Evans blue 3  h before euthanasia. Brains were then removed, and pictures were taken. 
To visualize histopathological changes in brain, tissue sections obtained from different parts of the brain were 
stained with hematoxylin and eosin as described previously and evaluated under light microscope at 10 × to 40 × 
 magnification11,12.
To compare parasites localized in brain parenchyma, anesthesized mice were performed intracardiac perfu-
sion, followed by euthanasia and removal of brains. Brains were immediately frozen in liquid nitrogen and kept 
at − 80 °C until processing. Brains were then homogenized and RNA was isolated using Qiagen RNeasy Plus mini 
kit according to manufacturer’s guidelines. cDNA synthesis was carried out using BioRAD iScript cDNA synthesis 
kit. SYBR green PCR master mix (Bio-Rad) was used to amplify 18S rRNA as well as host control genes, hprt, 
Figure 2.  S1823F mutation in ApiAP2 TF of PbNK65 does not induce experimental cerebral malaria. (A, B) 
Mice were inoculated with WT PbNK65S, mutant PbNK65F or WT PbANKAF iRBCs as in Fig. 1 and brains 
were collected from infected mice and uninfected controls at various time points. Sites of brain hemorrhage are 
shown as patchy dark blue colorations on brain photos of Evans blue injected mice. Photos are representative of 
more than 10 mice per group (A). (B) Tissue sections taken from different parts of infected mouse brains were 
stained with Hematoxylin and Eosin and then evaluated under light microscopy for histological signs of brain 
pathology. Sites of hemorrhage in 10 × magnified slides are shown with black arrow heads. RBC congested areas 
and signs of edema are shown in 40 × magnified slides with green and blue arrow heads respectively. 3 mice/
group/day were used for collecting tissue sections.
▸
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Figure 3.  PbNK65F- and PbNK65S-infected mice have similar quantities of  CD8+ T cells and iRBCs in their 
brains. (A, B) Mice were infected as indicated in Fig. 1. At days 10 or 21 post infection mice were injected 
intravenously with AF-488 conjugated CD45 specific Abs (in vivo) to label intravascular leukocytes. Brains were 
harvested shortly after and processed as detailed in methods section. Lymphocytes were then incubated with a 
second Ab including BV421 labelled CD45 specific Abs (in vitro) which stains both vascular and extravascular 
leukocytes. CD11b was used to gate out microglia and CD8 was used to gate  CD8+ T cells. Within the  CD8+ 
T cell gate cells that are double positive for both CD45 stains are gated as intraluminal cells (purple gate) and 
cells that are single positive for only in vitro CD45 stain were gated as adluminal cells (green gate) (A). Absolute 
counts of parenchymal  CD8+ T cells are graphed (B). Each circle represents an individual mouse n.s. = P > 0.05 
(One way ANOVA with Dunnet’s multiple comparisons test). (C) qPCR comparisons of parasite levels in brain 
specimens taken at day 21 post infection from mice infected as indicated in Fig. 1. Each circle represents an 
individual mouse. n.s. = P > 0.05 (Welch’s T-test).
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gapdh, and ppia. The primer sequences used are as follows Pb-18S: 5′-AAG CAT TAA ATA AAG CGA ATA CAT 
CCT TAC -3′ and 5′-GGA GAT TGG TTT TGA CGT TTA TGT G-3′. The mouse hprt: 5′-TGC TCG AGA TGT GAT 
GAA GG-3′ and 5′-TCC CCT GTT GAC TGG TCA TT-3′, mouse gapdh: 5′-GTG GAG TCA TAC TGG AAC ATG TAG 
-3′ and 5′-AAT GGT GAA GGT CGG TGT G-3′, mouse ppia: 5′-TTC ACC TTC CCA AAG ACC AC-3′ and 5′-CAA 
ACA CAA ACG GTT CCC AG-3′, Geometric means of threshold cycle (CT) values of all three control genes were 
subtracted from the CT value of 18S rRNA gene and thus ΔCT values were obtained. Comparing these values 
between WT and mutant parasite infected brains was used to interpret any changes in parasite loads in the brains.
To distinguish circulating  CD8+ T cells and  CD8+ T cells that were recruited to brain parenchyma, parasite 
infected C57BL/6 mice were injected in tail vein with 200 µl PBS solution containing 12 µl AF488 conjugated 
anti mouse CD45.2 (Biolegend, Catalog No: 109816). Fluorescently labelled antibody was allowed to circulate 
for 2 min which resulted in labeling of all intraluminal leukocytes. Mice were then immediately euthanized, and 
brains were removed. Lymphocytes from brain were harvested as previously  described11,27. Single cell suspensions 
of lymphocytes were stained with Live/DEAD Near IR (Thermofisher) viability dye as well as BV785 conjugated 
anti CD8 (to label  CD8+ T cells), BV605 conjugated anti CD11b (to gate out microglia) and BV421 conjugated 
anti mouse CD45.2 to label all leukocytes. Flow cytometry analysis was carried out using BD LSR II and data 
was analyzed using Flowjo software.  CD8+ T cells that were stained with both BV421 and AF488 were from the 
Figure 4.  Mutating the ApiAP2 TF of PbANKA to ApiAP2 of PbNK65 does not alter its ECM inducing ability. 
(A, B) Mice were infected with  106 iRBC/mouse dose of mutant PbANKAS and WT PbANKAF parasites 
microanatomic changes showing dark colored hemorrhagic areas in Evans blue stained brains (A) and histologic 
changes showing hemorrhagic areas (black arrow heads) and RBC congested capillaries (green arrow heads) 
in hematoxylin and Eosin stained brain sections are shown (B). (C, D) Two different inoculation doses were 
used to infect mice and changes in parasitemia (C) and survival (D) are graphed. Each circle represents a single 
mouse and line represents mean for (C) Data is representative of two independent experiments.
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intravascular pool while  CD8+ T cells that were stained only with BV421 but not the intravascularly injected 
AF488 were from the adluminal pool.
Ethics statement. This study has no human participants. Animal experiments were carried out according 
to ACUC guidelines and NIH approved animal protocol: ASP No:LIG-2E.
Data availability
All data supporting these results are available from the corresponding authors upon request.
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